CDC Panel advises that other vaccines are preferred over J&J Shot | Health – nach Welt

THURSDAY, December 16, 2021 (HealthDay News) – Following ongoing reports of a rare but life-threatening coagulation disorder related to the Johnson & Johnson coronavirus vaccine, a federal advisory board on Thursday recommended that the Pfizer and Moderna shots be the preferred ones Choices for Americans.

the Advisory Committee on Vaccination Practices (ACIP), which makes vaccine recommendations to the US Centers for Disease Control and Prevention, voted unanimously on Thursday afternoon on “updated recommendations for use” of the single-dose vaccine Agenda Of the meeting.

So far there have been around 16 million people fully vaccinated with the J&J vaccine in the United States, compared to about 73 million at Moderna and over 113 million at Pfizer.

The panel of experts heard updated information on thrombosis and thrombocytopenia syndrome (TTS), a rare blood clotting disorder associated with J & J’s vaccine but not the Pfizer or Moderna vaccines.

According to the New York Times, There is evidence that the risk of developing TTS from the J&J vaccine, although still extremely rare, was greater than originally thought. In total, the CDC reviewed data showing that by the end of August a total of 54 cases had been reported in people who had received the syringe. That’s 3.8 cases per 1 million people – still very low, but higher than originally estimated.

No such risk has occurred for people who received the Moderna or Pfizer vaccines.

At the same time, laboratory studies have shown that the vaccine offers little protection against the Omicron variant Just said.

One of the members of the advisory board, Dr. Pablo Sanchez, a pediatrician at Ohio State University, said he had already told patients to get other vaccines.

“I don’t recommend [the J&J vaccine] to the parents of my patients and I tell them to stay away from it, ”he told the Just.

Americans may already be turning away from the vaccine, and most who originally received the J&J vaccination did not turn to it as a booster.

However, some experts stressed that with the number of COVID cases rising again in the United States, it is certainly not the time to say no to a vaccine.

“It is really important, however, that we do not eliminate this vaccine entirely,” said Dr. Jason Goldman the Just. He is a representative of the American College of Physicians and an Assistant Professor of Clinical Biomedicine at Florida Atlantic University.

Currently, the J&J vaccine is approved for use in people aged 18 and over and can be used as a booster dose for adults fully vaccinated with the J&J, Pfizer, or Moderna vaccines.

But on Tuesday the FDA examined the J&J vaccine and said people with a history of TTS shouldn’t get it.

“You should not receive the Janssen COVID-19 vaccine if you have had a severe allergic reaction, a severe allergic reaction to any of the ingredients in this vaccine, or a blood clot with low platelet counts after a previous dose of this vaccine [blood cells that help your body stop bleeding] after Janssen COVID-19 vaccine or after AstraZeneca’s COVID-19 vaccine [not authorized or approved in the United States]“Said the agency in an updated data sheet for vaccine recipients and carers.

Clotting problems with the J&J vaccine first appeared in April when it was early Reports from TTS resulted in a brief pause in vaccine use. The CDC has since continued to monitor TTS-related cases related to the vaccine.

Both the CDC and FDA have said that people receiving the J&J vaccine – especially women under 50 – should look out for symptoms a week or two after vaccination, which include severe or persistent headaches or blurred vision. Shortness of breath; Chest pain; Leg swelling; persistent abdominal pain; or easy bruising or small spots of blood under the skin outside of the injection site. If any of these symptoms occur, patients should see a doctor immediately.

Jake Sargent, a spokesman for Johnson & Johnson, said the Washington Post that the company’s updated data sheet includes the latest information from the FDA about the rare disease.

“We are committed to understanding and communicating all known risks, including rare occurrences of [the blood clot condition], and do your utmost to help raise awareness of the signs and symptoms of this rare occurrence, ”he said.

More information

Visit the US Centers for Disease Control and Prevention to find out more about the Safety profile of the J&J vaccine.

THOSE: CNN; Washington-Position; New York Times


Leave a Reply

Your email address will not be published.